“This momentum reflects the dedication of our team and our commitment to our strategic objectives.” (CEO)
“We set new first-quarter records with more than 29,000 pump shipments worldwide and $247 million in sales.” (CFO)
“Gross margin for the quarter exceeded expectations at 55%, an improvement of nearly five percentage points year over year and the highest first-quarter gross margin in the company’s history.” (CFO)
“We are reaffirming our annual 2026 guidance as we continue to execute on our bold business model transformation in both the U.S. and international markets.” (CFO)
“We plan to file our 510(k) submission for the Mobi Tubeless in the second quarter.” (CEO)
Prepared Metrics
指标
数值
说话人/背景
全球泵出货量
>29,000台 (Q1)
CFO
全球销售额
$247M (Q1)
CFO
美国销售额
$161M (Q1)
CFO
国际销售额
$86M (Q1)
CFO
毛利率
55% (Q1)
CFO
调整后EBITDA占销售额
~1% (Q1)
CFO
自由现金流
$5M (Q1)
CFO
期末现金及投资
$570M
CFO
全年全球销售额指引
$1.065B–$1.085B
CFO
全年毛利率指引
56%–57%
CFO
全年调整后EBITDA指引
5%–6%
CFO
Q&A Batch (1-5 of 20)
Q1 — Matthew Stephan Miksic
Topic: Market growth drivers and seasonality in Q1
Key points:
U.S. pump shipments had a ~30% sequential decline from Q4, in line with expectations; no unusual seasonality observed.
Growth drivers cited as “all of the above”: new product launches, business model transformations, type 2 market expansion, and new technology.
Market remains large and underpenetrated; multiple pump companies performed well in 2025.
Mgmt stance: Bullish — strong conviction in growth trajectory due to technology and business model changes.
Q2 — Christopher Thomas Pasquale
Topic: International revenue drivers and one-time items
Key points:
International pump revenue grew year-over-year despite lower pump shipments, partly due to currency fluctuation favorability.
Year-over-year comparison affected by a ~$5 million timing shift in Q1 2025 vs. Q2 2025.
Within Q1: estimated ~$5 million headwind from going direct in certain markets; only ~$1 million realized, with $3–$4 million pushed to Q2.
One-time accounting benefit in Swiss market largely offset by infusion set shortage noise.
Mgmt stance: Neutral — acknowledges moving parts but sees strong demand and positive reception in direct markets.
Q3 — Matthew O’Brien
Topic: Mobi Tubeless launch timeline and revenue impact
Key points:
Submission on track for Q2; clearance expected in second half of 2026, with some FDA uncertainty.
No revenue from Mobi Tubeless included in 2026 guidance; phased commercialization (small groups → full launch) is standard practice.
If clearance occurs before Q4, management would aim to launch before year-end, but timing depends on FDA.
Mgmt stance: Cautious — uncertainty around FDA clearance and phased launch process; no disruption to existing quarters expected.
Q4 — Michael Holden Kratky
Topic: Pharmacy channel performance and 15% target
Key points:
U.S. pharmacy sales as a percentage ticked down from 7% in Q4 to 6% in Q1; not comparable to 2025 due to business model change (previous contracts had premium pump reimbursement).
Formulary coverage already at ~40% and expected to increase through the year.
Operational workflow changes (prescribing, patient engagement, order fulfillment) began late in Q1; early stages.
Mgmt stance: Bullish — conviction unchanged in ability to scale pharmacy channel to 15% for the year; early execution progress.
Q5 — David Harrison Roman
Topic: Pricing assumptions and rationality in pharmacy channel
Key points:
Competitors described as acting rationally on pricing; TNDM sees opportunity in pharmacy channel pricing already set for insulin pumps.
Guidance assumes ~$3.50 per month per patient for supplies, based on an array of contracts with varying rebate structures.
No sufficient experience yet to determine sustainable mix; baseline assumption remains unchanged.
Mgmt stance: Neutral — early stage with limited data; will update assumptions as volumes and experience grow.
Topic: U.S. new-start trends and 2026 growth outlook
Key points:
New starts were down slightly year over year in Q1 and down modestly sequentially, primarily due to regular seasonal impact.
Management models a slight Q1 decline with a return to growth for the rest of 2026.
Growth drivers: traction from new product launches, pharmacy channel removing upfront cost barrier.
Mgmt stance: Bullish — convicted in return to growth based on improving trends since mid-2025 and pharmacy momentum.
Q12 — Michael Polark
Topic: Process and incentives for converting existing DME patients to pharmacy
Key points:
Conversion requires checking benefits at quarterly order, sharing out-of-pocket (typically lower under pharmacy, especially with copay assistance), and obtaining a new prescription from physician.
Physician outreach is a bottleneck as many prefer to focus on non-pump patients.
Potential to move ~300,000 existing patients, significantly boosting revenue growth and margins.
Mgmt stance: Bullish — pharmacy conversion is a major focus area, seen as key driver for revenue and margin improvement.
Q13 — Analyst
Topic: Q1 cash flow generation and sustainability
Key points:
Q1 historically a heavy cash burn quarter; this Q1 showed positive EBITDA (1%) and cash flow generation, first time since 2022.
Improvement driven by cost discipline and focus on margin improvement alongside revenue growth.
Mgmt stance: Bullish — positive cash flow in a seasonally tough quarter demonstrates sustainable cost discipline.
Q14 — Elaine Cui
Topic: Gross margin cadence and drivers for 2026
Key points:
Q1 to Q2 gross margin relatively flat due to product mix: more supplies (lower margin than pumps globally) in the step-up.
Gross margin should step up from Q2 toward ~60% in Q4.
Drivers: pricing benefits from direct international operations and U.S. pharmacy conversion; Mobi scaling (pumps benefited in 2025, supplies will benefit in 2026).
Mgmt stance: Bullish — price and pharmacy conversion are prominent drivers; scaling benefits continue.
Q15 — Jonathan Block
Topic: International pump ASP and direct transition impact
Key points:
Q1 pump ASP benefited from a one-time accounting benefit in Switzerland (recognition of higher revenue from acquired distributor rental contracts).
Full-year guidance assumes international pump ASP in the $2,800–$2,900 range for the rest of 2026.
Mgmt stance: Neutral — Q1 ASP was elevated by a non-recurring item; normalized ASP expected to settle into guided range.